A once-weekly GLP-1RA was able to substitute for prandial insulin in 54% of people, substantially reducing the number of prandial insulin injections; glycemic control improved, with the added benefits of weight loss and less hypoglycemia in the GLP-1RA arm. Replacing prandial insulin with a weekly GLP-1RA can simplify basal plus prandial insulin treatments and achieve better outcomes in type 2 diabetes (Diabetes Care)
Diabetes News
Category: Medication
Insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes
iGlarLixi demonstrated similar or improved efficacy and safety versus other intensification choices from BI included in this study, providing a clinically relevant treatment option in people with T2D not well controlled on BI (Diabetes, Obesity and Metabolism)
Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study
These results demonstrate that switching to degludec from other basal insulins was associated with reduced rates of hypoglycaemia, irrespective of the definition used or baseline patient characteristics (Diabetes Therapy)
Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes
The glucose-lowering efficacy of SGLT-2i, and to a lesser extent DPP-4i, was greater in studies of predominantly Asian ethnicity compared with studies of predominantly white ethnicity. There was no difference seen by ethnicity for GLP-1RA (Diabetes Care)
Effect of dipeptidyl peptidase‐4 inhibitors on complement activation
All the 7 DPP‐4 inhibitors tested in the study directly inhibited functional activity of the lectin pathway in a dose‐dependent manner with varying potency in vitro. In vivo, MBL, sMAC, and C4b declined significantly during follow‐up in both groups without significant effect of sitagliptin (Diabetes/Metabolism Research and Reviews)
Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study
The MAGE study indicates that Gla-300, as part of a basal-bolus regimen, results in improved treatment satisfaction and reduced hypoglycemia fear in people with advanced T2DM (Diabetes Therapy)
Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes
When added to optimised insulin therapy, sotagliflozin improved glycaemic control and body weight and enabled more adults with T1D to achieve A1c goals without weight gain over 52 weeks, although there was more DKA relative to placebo (Diabetes, Obesity and Metabolism)
Influence of Renin-Angiotensin System Inhibitors on Lower–Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II
ACEi/ARB reduce the risk of pneumonia/influenza in people with type 2 diabetes (Diabetes Care)
Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control
Draft Guidance for Industry; Availability (FDA, USA)
15-LB: Ready-to-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia during Aerobic Exercise
RTUG 150 μg maintained euglycemia during prolonged, continuous, intense aerobic exercise. (Diabetes)
SGLT2i: beyond the glucose-lowering effect
The information presented provides a theoretical basis for the clinical prevention and treatment of diabetes and its complications and for the development of new glucose-lowering drugs (Cardiovascular Diabetology)
Exenatide ER in patients with Type 1 diabetes with and without residual insulin production
Treatment with exenatide ER may have short‐term benefits in some individuals with T1D who are overweight or with detectable levels of C‐peptide, but short term improvements were not sustained (Diabetes, Obesity and Metabolism)
Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors
Pioglitazone use decreased the risk of new-onset ischemic stroke in Asian patients with type 2 DM and CV risk factors (Cardiovascular Diabetology)
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
We found no substantial increase in the likelihood of a positive test for Covid-19 or in the risk of severe Covid-19 among patients who tested positive in association with five common classes of antihypertensive medications (NEJM)
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19 (NEJM)
VERTIS CV
Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure (AJMC)
Diabetes medications with cardiovascular protection as we enter a new decade
Can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? (ABCD)
Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine)
The Leader study has shown that the rate of the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo (ABCD)
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
This implies that liraglutide and semaglutide may be beneficial for patients with type 2 diabetes, irrespective of their baseline BP (Diabetes Obesity and Metbolism)
Glucagon‐like peptide 1 receptor agonists and sodium glucose co‐transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta‐analysis
GLP‐1 RA/SGLT2i combination therapy seems to reduce HbA1c, body weight and systolic blood pressure without increasing the risk for severe hypoglycemia compared to either GLP‐1 RA or SGLT2i. No robust conclusions can be made regarding long‐term effectiveness or effect on cardiovascular outcomes (Diabetes, Obesity and Metabolism)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 41
- Next Page »
Glycosmedia is also available as an App: